Table 1.
Patient demographics and clinical variables.
| Patient demographics | All | Cardiac hepatopathy (n=56) | No cardiac hepatopathy (n=132) | p-value |
|---|---|---|---|---|
| Age (years) | 62±17 | 61±16 | 62±17 | 0.97 |
| Male (%) | 55 | 50 | 57 | 0.39 |
| Body surface area (m2) | 1.9±0.3 | 1.8±0.2 | 1.9±0.3 | 0.32 |
| Hypertension (%) | 81 | 86 | 79 | 0.26 |
| Diabetes (%) | 41 | 39 | 42 | 0.73 |
| Creatinine | 1.1 [1, 1.5] | 1.2 [1, 1.7] | 1.1 [1, 1.5] | 0.09 |
| Statin use (%) | 34 | 23 | 39 | 0.07 |
| Anti-platelet use (%) | 44 | 46 | 43 | 0.72 |
| ACEI or ARB use (%) | 46 | 46 | 45 | 0.90 |
| Beta blocker use (%) | 61 | 60 | 61 | 0.90 |
| Loop diuretic use (%) | 61 | 58 | 62 | 0.63 |
| Amiodarone use (%) | 2 | 5 | 1 | 0.14 |
| Warfarin use (%) | 24 | 17 | 27 | 0.22 |
| AST >100 mg/dL (%) | 13 | 45 | 0 | <0.001 |
| Alk-phos >200 mg/dL (%) | 14 | 48 | 0 | <0.001 |
| Total bilirubin >2.0 mg/dL (%) | 18 | 61 | 0 | <0.001 |
Normal data are presented as the mean ± standard deviation. Non-normal data are presented as the median [interquartile range]. ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; AST – aspartate aminotransferase; Alk-phos – alkaline phosphatase.